SCHEMBL4285941

SCHEMBL4285941

CN(CCCCN)CC(N)=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.56
PAOX Q6QHF9 3/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
NFKB1 P19838 2/20 0.34
CYP2D6 P10635 1/20 0.34
BLM P54132 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 2/20 0.33
THRB P10828 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PLG P00747 1/20 0.33
ALOX15 P16050 1/20 0.33
SLC6A2 P23975 1/20 0.33
RECQL P46063 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KDM4A O75164 1/20 0.31
HIF1A Q16665 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4552798 0.88 CHRM2 (0.44) CHRM2HDAC3HDAC4HDAC1HDAC7
SCHEMBL10044461 0.87 CHRM2 (0.56) CHRM2PAOXMAOAMAOBNFKB1
SCHEMBL3293010 0.85 CHRM2 (0.43) CHRM2DDB1CRBNGGPS1FDPS
SCHEMBL10044468 0.85 CHRM2 (0.60) CHRM2PAOXMAOAMAOBNFKB1
SCHEMBL13573476 0.85 CHRM2 (0.60) CHRM2PAOXMAOAMAOBNFKB1
SCHEMBL21320204 0.84
SCHEMBL24112603 0.83 CHRM2 (0.56) CHRM2PAOXNFKB1CYP2D6BLM
SCHEMBL8381419 0.83 GGPS1 (0.46) KMT2AMEN1KDM4ACYP1A2GGPS1
SCHEMBL7348316 0.81 S1PR2 (0.48) KMT2AMEN1KDM4ACYP1A2GGPS1
SCHEMBL16562360 0.81 S1PR2 (0.48) KMT2AMEN1KDM4ACYP1A2GGPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300010-B1 PYRAZINE DERIVATIVES AS EPITHELIAL SODIUM CHANNEL BLOCKERS NOVARTIS AG (CH) 2015-03-04 EP disclosed
US-8236808-B2 Pyrazine derivatives as ENAC blockers NOVARTIS AG (CH) 2012-08-07 US disclosed
WO-2009150137-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 WO disclosed